Product Information
SPIRIVA HANDIHALER 18 MCG CAP is a brand product labeled by Boehringer Ingelheim Pharmaceuticals Inc., priced at $11.6790 per EA under NDC 00597007575. Its NADAC has been published 281 times since Feb 19, 2014.
FDA first approved this application on Jan 30, 2004. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
18 ug/1
Manufacturer
Boehringer Ingelheim Pharmaceuticals Inc.NDC
00597007575
Classification
Brand
Dosage Form
CAPSULE
Route
ORAL; RESPIRATORY (INHALATION)
Effective Date
9/23/2026
Active Ingredients
TIOTROPIUM BROMIDE MONOHYDRATEApproval Type
New Drug (NDA)
FDA Application
NDA021395FDA Approved
1/30/2004
TE Code
AB
On Market Since
10/11/2005
Pharmacological Classes
Price Statistics
The NADAC for SPIRIVA HANDIHALER 18 MCG CAP has been published 281 times since Feb 19, 2014, and over the history we have for it it has declined 23.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $11.6790 per EA |
|---|---|
| All-time high | $19.3463 (Jan 1, 2025) |
| All-time low | $11.5764 (Jun 18, 2025) |
| 52-week high | $11.7350 |
| 52-week low | $11.6143 |
| Median price | $13.0192 |
| Average price | $14.0239 |
| Largest weekly change | +48.0% (Apr 17, 2024) |
| Weeks tracked | 281 |
| Tracking since | Feb 19, 2014 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 9% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Boehringer Ingelheim Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
TIOTROPIUM BROMIDE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anticholinergic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SPIRIVA HANDIHALER 18 MCG CAP?
The current National Average Drug Acquisition Cost (NADAC) for SPIRIVA HANDIHALER 18 MCG CAP, manufactured by Boehringer Ingelheim Pharmaceuticals Inc., is $11.6790 per EA (NDC 00597007575), effective Sep 30, 2026.
How has the price of SPIRIVA HANDIHALER 18 MCG CAP changed over time?
Over the history we have for it, the NADAC for SPIRIVA HANDIHALER 18 MCG CAP has declined 23.4%. It has been tracked across 281 weekly CMS publications since Feb 19, 2014.
What are the highest and lowest recorded NADAC prices for SPIRIVA HANDIHALER 18 MCG CAP?
Since Feb 19, 2014, the NADAC for SPIRIVA HANDIHALER 18 MCG CAP has ranged from a low of $11.5764 (Jun 18, 2025) to a high of $19.3463 (Jan 1, 2025), with a median of $13.0192 per EA.
Are there cheaper alternatives to SPIRIVA HANDIHALER 18 MCG CAP?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, SPIRIVA HANDIHALER 18 MCG CAP, is $10.6048 per EA — about 9% below SPIRIVA HANDIHALER 18 MCG CAP.
Who manufactures SPIRIVA HANDIHALER 18 MCG CAP?
SPIRIVA HANDIHALER 18 MCG CAP (NDC 00597007575) is labeled by Boehringer Ingelheim Pharmaceuticals Inc., and CMS classifies it as a brand product.